TMDX logo

TransMedics Group, Inc. Stock Price

NasdaqGM:TMDX Community·US$3.7b Market Cap
  • 3 Narratives written by author
  • 0 Comments on narratives written by author
  • 123 Fair Values set on narratives written by author

TMDX Share Price Performance

US$107.29
-26.95 (-20.07%)
36.9% undervalued intrinsic discount
US$170.00
Fair Value
US$107.29
-26.95 (-20.07%)
36.9% undervalued intrinsic discount
US$170.00
Fair Value
Price US$107.29
AnalystHighTarget US$170.00
AnalystConsensusTarget US$138.88
AnalystLowTarget US$114.00

TMDX Community Narratives

AnalystHighTarget·
Fair Value US$170 30.6% undervalued intrinsic discount

Transplant Logistics Will Meet Demand From An Aging World

0users have liked this narrative
0users have commented on this narrative
3users have followed this narrative
AnalystConsensusTarget·
Fair Value US$138.88 15.0% undervalued intrinsic discount

Organ Transplant Demand And International Expansion Will Unlock Future Opportunities

2users have liked this narrative
0users have commented on this narrative
55users have followed this narrative
AnalystLowTarget·
Fair Value US$114 3.6% overvalued intrinsic discount

Cost Pressures And Supply Risks Will Weaken Transplant Market Viability

0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative

TransMedics Group, Inc. Key Details

US$531.3m

Revenue

US$213.6m

Cost of Revenue

US$317.7m

Gross Profit

US$246.0m

Other Expenses

US$71.7m

Earnings

Last Reported Earnings
Jun 30, 2025
Next Reporting Earnings
n/a
Earnings per share (EPS)
2.10
Gross Margin
59.79%
Net Profit Margin
13.49%
Debt/Equity Ratio
160.6%

TransMedics Group, Inc. Competitors

 
 
 
 
 
 
 
 
 
 
 
 

Snowflake Analysis

High growth potential with solid track record.

0 Risks
4 Rewards

About TMDX

Founded
1998
Employees
728
CEO
Waleed Hassanein
WebsiteView website
www.transmedics.com

TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its OCS includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart, a technology for preservation of DBD donor hearts deemed unsuitable due to limitations of cold storage and for ex vivo reanimation, functional monitoring, and beating-heart preservation of donation-after-circulatory-death hearts; and OCS Liver for the preservation of DBD and DCD of donor livers. The company also developed national OCS program, a turnkey solution for outsourced organ retrieval; and provides OCS organ management and logistics services, including aviation and ground transportation, and other coordination activity. The company was founded in 1998 and is headquartered in Andover, Massachusetts.

Market Insight

Q4 2025 is off to a flying start with record highs being printed left, right, and center. US and Japanese stocks made fresh new highs, while the gold price powered through $4,000 for the first time, and Bitcoin crossed the $126k level. Is this all a case of USD weakness, irrational exuberance, or solid fundamentals? This week, we are reviewing Q3 market performance, Q2 earnings season, and the outlook heading into the end of 2025…
Continue reading

U.S. Market Performance

  • 7 Days: -2.7%
  • 3 Months: 5.1%
  • 1 Year: 13.4%
  • Year to Date: 11.7%
Over the last 7 days, the market has dropped 2.7%, driven by a loss of 2.5% in the Information Technology sector. As for the longer term, the market has actually risen by 13% in the last year. As for the next few years, earnings are expected to grow by 15% per annum. Market details ›